To The Editor in Chief
World Journal of Virology
Dear Editor,

Enclosed, please find our revised manuscript (Manuscript NO: 68838) entitled “Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy”. As suggested by the reviewers, we have revised the paper. The changes were highlighted using track changes. Our point-by-point replies to the reviewers are as follow:

Comments from the Editors and Reviewers:

2 Peer-review report

Reviewer #1:
Sahu and colleagues have authored a letter in response to a recent review in this journal. The letter makes a few good points but there are a few errors which need attention - Given the title it would be useful if the authors could make some suggestions as to what this therapeutic strategy might involve – The article by Abid et al that they reference several times is a viewpoint and does not contain original data.

In addition it reviews COVID-19 treatment in the context of immune checkpoint blockade and CAR T cells and makes a few recommendations for this type of treatment - it does not mention standard chemo(immuno)therapy which the vast majority of lymphoma patients will receive - They reference this paper again after quoting figures that 85% of patients with lymphoid malignancies will be admitted with 9% needing ICU and 34.5% mortality - but these figures are not in this reference - They touch on the efficacy of COVID-19 vaccines in lymphoma patients as a result of very recent publications. As this data has been published since the Riches review this would be a good area to expand upon.

Answer: Thank you very much for the critical review. As per the reviewer suggestion, we have corrected the manuscript.
Reviewer #2: Dear author, Well written article
Answer: Thank you very much.

Reviewer #3: The manuscript is well written and need of the present times.
Answer: Thank you very much.

Corresponding Author
Dr. Henu Kumar Verma